NeoImmuneTech, Inc. (NIT) is currently under Phase I clinical trial in healthy normal volunteers, with strong non-clinical scientific evidences.
NIT will soon initiate single agent Phase Ib study in cancer patients in collaboration with major cancer centers and universities in the US and South Korea.
NIT pursues combination with leading immunotherapeutics such as an immune checkpoint inhibitor, a cancer vaccine, etc.
On top of its previous in vitro, in vivo studies, NIT has been conducting many proof-of-concept animal studies in parallel to progressing clinical trials in order to strengthen our beliefs and better design the clinical protocols. For instance, NT-I7 has demonstrated a strong enhancement of efficacy of HPV targeted therapeutic cancer vaccine when treated as a combination in a mice cancer model.